Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.

Small-molecule inhibitors targeting RAS/RAF disrupt allosteric RAF conformation, effectively treating diverse RAS-driven cancers with a broad-spectrum approach.

• Why it matters: RAS mutations are common in cancers and pose a challenge for targeted therapy, especially due to resistance and mutation variability, necessitating new broad-spectrum inhibitors.
• What they did: Researchers performed multimodule drug screening and structural analysis, identifying compounds that covalently bind to RAF's RAS-binding domain and allosterically inhibit RAS/RAF interaction across multiple RAS mutations.
• The result: The compounds showed potent antitumor activity in preclinical models, including RAS-mutant and wild-type cancers, and overcame resistance in BRAF V600E-melanoma, paving the way for new therapeutic strategies.